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ABSTRACT
The purpose of this research was to develop liposomal dry
powder aerosols for protein delivery. The delivery of stable
protein formulations is essential for protein subunit vaccine
delivery, which requires local delivery to macrophages in the
lungs. β-Glucuronidase (GUS) was used as a model protein
to evaluate dry powder liposomes as inhaled delivery vehi-
cles. Dimyristoyl phosphatylcholine:cholesterol (7:3) was
selected as the liposome composition. The lyophilization
of liposomes, micronization of the powders, aerosoliza-
tion using a dry powder inhaler (DPI), and in vitro aero-
dynamic fine particle fraction upon collection in a twin-
stage liquid impinger were evaluated. After lyophilization
and jet-milling, the total amount of GUS and its activity,
representing encapsulation efficiency and stability, were
evaluated. The GUS amount and activity were measured
and compared with freshly-prepared liposomes in the pres-
ence of mannitol, 43% of initial GUS amount, 29% of
GUS activity after lyophilization and 36% of GUS amount,
22% of activity after micronization were obtained. Emit-
ted doses from dry powder inhaler were 53%, 58%, 66%,
and 73% for liposome powder:mannitol carrier ratios of
1:0, 1:4, 1:9, and 1:19. Fifteen percent of the liposome
particles were less than 6.4 μm in aerodynamic diameter.
The results demonstrate that milled liposome powders
containing protein molecules can be aerosolized effectively
at a fixed flow rate. Influences of different cryoprotectants
on lyophilization of protein liposome formulations are re-
ported. The feasibility of using liposomal dry powder
aerosols for protein delivery has been demonstrated but
further optimization is required in the context of specific
therapeutic proteins.
KEYWORDS: protein, liposome, lyophilization, dry pow-
ders, aerosol, pulmonary deliveryR
INTRODUCTION
Drug delivery via the lungs received considerable attention
throughout the 1990s.1 Difficulties associated with the de-
livery of peptides and proteins, coupled with the likelihood
of acceptable pulmonary bioavailability led to interest in
their presentation for absorption via the lungs.
Liposomes are promising vehicles for pulmonary drug
delivery owing to their capacity to target drug to cells, such
as macrophages, and to alter pharmacokinetics of drugs.2,3
They also provide sustained release, prevent local irritation,
increase drug potency, reduce toxicity, and uniformly
deposit active drugs locally.4,5
Some proteins and enzymes, such as glutathione,6 super-
oxide dismutase,7 and catalase,8 have been encapsulated by
liposomes to improve their pulmonary delivery, and most
of them were administered intratracheally into the respira-
tory tract in liquid-based liposomes.2 Nebulizers have been
used extensively for the delivery of liposomes.9,10 However,
delivery of liposomes by nebulization may be hampered by
long-term instability problems that lead liposome disper-
sions to undergo physiochemical changes resulting in
leakage of the encapsulated drug.11 Among formulations
employed for drug delivery to the lungs, dry powders stand
out because of the stability of drugs and formulations.
Dry powder delivery is an important inhalation technol-
ogy. Dry powder products may consist of drug alone or
blended with excipient that acts as a carrier for delivery to
the lungs.12 Freeze-dried liposomes have been prepared for
aerosol delivery to improve liposome stability.13 Another
method of preparing dry powder liposomes is by spray-
drying.14 Some small molecules, such as Budsonide15 and
Ketotifen,16 have been prepared in freeze-dried liposomes
to form a dry powder dispersion for inhalation. These in-
vestigations demonstrated the possibility of delivering lipo-
somally entrapped small molecules to terminal bronchioles
in therapeutic doses and offered the exciting possibility of
aerosol delivery as dry powder formulations.
Few studies have been performed to evaluate whether thera-
peutic proteins in liposomes can be aerosolized into the respi-
ratory tract in dry powder formulations. Superoxide dismutase
was encapsulated in the spray-dried liposomes to evaluate
respirable properties.14 In our present studies, a model pro-
tein was used to evaluate both the feasibility of delivering
dry powder liposome formulations for protein and, more
importantly, whether the process of lyophilization could be
used to prepare dry powders suitable for pulmonary delivery.
The majority of studies describing pulmonary delivery of
proteins and peptides have focused on systemic delivery of
drugs.17-21 The present studies are concerned with the
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delivery of proteins for local activity, specifically the deliv-
ery of subunit vaccines to elicit cell-mediated responses for
tuberculosis prevention.22 Many of these proteins are in lim-
ited supply and a formulation strategy requires an approach
validated using model proteins. The enzyme, β-glucuronidase
(GUS), was evaluated as a model protein in preliminary
studies of liposome formulation, lyophilization, microniza-
tion, and aerodynamic size distributions. The specific aims
of the study are to (1) prepare liposomes containing the model
protein, (2) adopt methods for lyophilization and milling that
result in fine particles suitable for inhalation, and (3) to char-
acterize the powder in terms of protein structure or activity
before and after the various processes and aerosolization.
MATERIALS AND METHODS
Materials
Dipalmitoyl phosphatidylcholine (DPPC), dimyristoyl phos-
phatidylcholine (DMPC), dioleoyl phosphatidylcholine
(DOPC), Dioleoyl trimethylammonium propane (DOTAP),
dioleoyl phosphatidylglycerol (DOPG), and cholesterol (CH)
were purchased from Avanti Polar Lipids, Inc (Alabaster,
AL). D-mannitol, sucrose, sodium phosphate monobasic,
HEPES, ammoniumferrothiocyanate, phenolphthalein glu-
curonic acid, and GUS from bovine liver (type B-1) were
purchased from Sigma (St Louis, MO). Povidone (polyvinyl-
pyrrolidone [PVP],Mw40 000) was fromSpectrum (Gardena,
CA). PAGE gel (Bio-rad ready gels, 7.5% Tris-HCl) and pro-
tein quantification kit DC protein assay package were from
Bio-Rad (Hercules, CA). All materials were used as received.
Methods
Liposome Preparation
Different components of liposomes were prepared by
dehydration-rehydration and then freezing- thawing meth-
ods. Different fatty acid chain length (DOPC, DMPC,
DPPC) and charged lipids (DOPG and DOTAP) together
with cholesterol were screened for encapsulation effi-
ciency. DOPC- CH (7:3), DOPC-CH-DOTAP (7:2:1, 7:1:2),
DOPC-CH-DOPG (7:2:1), DMPC-CH (7:3) and DPPC-CH
(7:3) were used as lipid components. Lipids were dissolved
in chloroform, and the solvent was evaporated by nitrogen.
The lipid films were put into vacuum desiccators in the
presence of dry silica gel for 2 hours to remove chloroform.
The dry lipid films were hydrated in 20 mM sodium phos-
phate buffer (pH 7.4), containing 25 mM lipids, 250 mM
sugar, and 3.75 mg/mL β-glucuronidase. The multilamellar
vesicles were freeze-thawed for 20 cycles, −80°C to 37°C,
using liquid nitrogen and temperature-controlled water bath.
The free proteins were removed by centrifugation at g =
25 000, 10°C for 30 minutes. The liposome pellets were
rinsed (4 times) until the ratio of free protein in the super-
natant to encapsulated protein in liposomes was less than 2%.
The freshly prepared liposomes were subjected to quasi-
elastic, dynamic light scattering particle size analysis (NIC-
OMP Submicron Particle Sizer autodilute, model 370, Santa
Barbara, CA). A volume of 600 μL 0.1% Triton X-100 was
added into 400 μL freshly prepared liposomes to disrupt the
liposome vehicles for protein quantification and activity assay.
Liposome Lyophilization
Liposome suspensions were frozen in dry ice-acetone. The
liposomes were lyophilized (Labconco Freeze Dry System,
Freezone 6, Kansas City, Missouri) at −45°C for 48 hours.
Milling
One gram of the lyophilized liposomes was micronized (Trost
GEM-T jet mill, Plastomer Products, Newton, NJ) with dry
nitrogen gas (60 and 40 pounds per square inch gauge [psig]
of pusher and grinder pressure, respectively). The powders
were collected from cyclone and jar. The micronized parti-
cles were stored in a desiccator containing silica gel under
vacuum at room temperature (20°C-21°C) until required.
Powders were stored for a maximum of 2 days before
characterization and further assay were performed.
Characterization of Liposomes
Lyophilized liposomes, before and after jet-milling, were
characterized by Scanning Electron Microscopy (SEM,
model 6300, JEOL, Peabody, NY). The stubs were coated
with gold-palladium alloy (150-250Å) using a sputter coater
(Polaron 5200, Structure Probe Supplies, West Chester, PA).
The coater was operated at 2.2k V, 20 mV, 0.1 torr (argon)
for 90 seconds. An accelerating voltage of 15 kV was used.
Dry Liposome Reconstitution
Quantities of lyophilized or jet-milled liposomes were re-
constituted in 20 mM phosphate buffer (pH 7.4) to original
concentrations in preparation. Samples were vortexed for
2 seconds and centrifuged twice to separate the free drug at
g = 25 000, 10°C for 30 minutes. A volume of 1000 µl of
0.1% Triton X-100 was added into the lipid pellets to disrupt
lipid vesicles for protein quantification and activity assay.
GUS Quantification and Activity Assay
Lowry protein quantification method (Bio-Rad DC protein
assay) was used to determine the total amount of GUS.23
The standard curve of UV absorbance (λmax = 750 nm)
versus GUS concentration was prepared. Absorbance was
linear with respect to GUS concentration from 10 μg/mL to
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100 μg/mL with R2 = 0.998. Lipid interference was negli-
gible when lipid concentration was lower than 0.08mM. In
all the quantification assays, lipid concentrations were un-
der 0.08mM.
The substrate employed in the enzyme activity assay was
phenolphthalein glucuronic acid. The UV absorption ver-
sus mass of phenolphthalein curve was established in the
phenolphthalein mass range of 0 to 50 μg with R2= 0.999.
The units of enzyme were calculated as follows:
& Units/mL enzyme = (μg phenolphthalein released)(2)
(df)/0.1
& 2 = conversion factor from 30 minutes to 1 hour as
per the unit definition
& df = dilution factor
& 0.1 = volume (in mL) of enzyme used
A volume of 0.7 mL sodium acetate buffer (pH 5.0), 0.7 mL
1.2 Mm substrate solution, and 100 μL enzyme sample were
incubated in a 37°C water bath for 30 minutes. Glycine
buffer (pH 10, 5 mL) was added to stop enzyme action. The
hydrolyzed phenolphthalein absorbance was measured at
UV 540 nm.24,25
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
Lyophilized and micronized liposome powders were mixed
with 0.1% Triton X-100. The lipids were extracted in chlo-
roform. The fresh β-glucuronidase (in phosphate buffer),
upper phase of lyophilized and jet-milled extracted samples
were mixed with NuPAGE sample buffer and NuPAGE
reducing reagent. The fresh standard solution of GUS was
used as a control. The mixtures underwent the sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (7.5%) in SDS-Tris-HCl buffer, 140 V. The gel
was stained with Coomassie blue and then destained with
ethanol-acetic acid-water destaining solution. The gel image
was scanned on a gel scanner (model GS-700 imaging
denitomer, Bio-Rad) equipped with Quantity One software.
Emitted Dose Determination
The mass ratios of micronized liposome to carrier (D-
mannitol 45-75 um) were 1:0, 1:4, 1:9, and 1:19. Themixtures
were blended with mortar and pestle. Powder mixtures of
sugar and liposome (40 mg) were weighed into No. 3 gela-
tin capsule. A dry powder inhaler (Inhalator, Boehringer
Ingelheim, Ridgefield, CT) was attached to the mouthpiece
of emitted dose apparatus (Dose uniformity apparatus B
in United States Pharmacopeia [USP]). The capsule was
pierced and the powder was emitted at 60 L/min for 10 sec-
onds. The tube and filter were rinsed with chloroform. The
mannitol was extracted using water to reduce the turbidity
in organic phase. Finally the lipid contents were quantified.
Fine Particle Fraction Evaluation
A twin-stage liquid impinger was used to estimate the
aerodynamic fine particle fraction of micronized liposome.
Six capsules, each containing 40 mg mixed powder (mass
ratio 1:4 liposome powder to mannitol carrier), were emptied
sequentially from the Inhalator at 60 L/min for 10 seconds.
The lipid content and protein activity assays were deter-
mined for each liposome powder following rinsing with
20 mM phosphate buffer. The lipid suspensions underwent
lipid assay by adding chloroform and the protein activity
assays by adding 0.1% Triton X-100.
Phospholipid Quantification Assay
The phospholipid contents of liposomes were determined
by a modification of an assay by Stewart, employing an
ammoniumferrothiocyanate dye.26 The absorbance of the
phospholipid-dye complexes in chloroform was measured
at 470 nm.
RESULTS AND DISCUSSION
GUS Encapsulation in Different Liposome Components
Different components of liposomes were studied for the
encapsulation of GUS. CH was included in all preparations
to confer fluidity to the gel-phase membrane (below its
transition temperature) and to strengthen liquid crystal-
phase membrane to prevent a membrane phase transition.27
DOPC-CH (7:3), DOPC-CH-DOTAP (7:2:1, 7:1:2), DOPC-
CH-DOPG (7:2:1), DMPC-CH (7:3), and DPPC-CH (7:3) in
liposome preparation gave 3.9%, 17%, 13.6%, 19.2%, 19%,
and 17.1% encapsulation efficiency, respectively. DMPC-
CH (7:3) was selected for further investigation owing to
encapsulation efficiency, concern for stability of protein, and
ease of use. Storing the mixture of DMPC-CH lipid and
aqueous protein solution at 4°C overnight before freezing-
thawing cycles increased the encapsulation efficiency to
43%. This may be explained by a time dependent interaction
between protein and lipid while the protein encapsulation
efficiency depends on this interaction.28 The size distribu-
tion of multilamellar vesicles of DMPC-CH in mannitol-
phosphate buffer was 3.07 ± 0.35 μm as measured by
dynamic light scattering.
Influences of Lyophilization and Jet-milling on Liposome
Encapsulation and Protein Activity
Lyophilization is considered a promising means of extend-
ing the shelf-life of liposomes. However, both freezing and
drying can induce structural and functional damage to
liposomes as well as to proteins. Saccharides are frequently
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used as the cryoprotectants in lyophilization for stability of
liposomes and proteins. D-Mannitol was used for this
purpose in the first trial of lyophilization.
The mass yields from milling lyophilized powder were in
the range of 50.1% to 52.1%. Compared with the freshly
prepared liposomes, the retained total amount of protein
and the activity were 43% and 29% after lyophilization and
36% and 22% after micronization (Figure 1).
Scanning electron micrographs (SEM) of DMPC-CH-
mannitol powder with and without GUS are shown in
Figure 2. Figures 2A and 2C show amorphous lyophilized
liposome-carbohydrate powders. The porous structure of
the cake allows rapid dispersion of the powder for aqueous
reconstitution and aids in milling efficiency to micronize
powders. The micronized liposome powders are shown in
2B and 2D. The particle sizes from SEM are ~2 to 3 μm,
within the respirable particle size range. The particle sizes
of 3 μm may be ideal for maximizing pulmonary depo-
sition of dry powders.13 Micronized powders appeared to
be aggregated. The liposome control and sample exhibited
similar morphologies. The presence of GUS did not appear
to change liposome behavior compared with liposome
control. The retentions of protein contents were 43% and
36% in amount and 29% and 22% in activity before and
after jet milling. Lyophilization caused protein loss in terms
of poor encapsulation efficiency and stability.
β-Glucuronidase is a tetramer. In the presence of reducing
reagent and SDS buffer solution, the standard GUS, lyo-
philized, and jet-milled GUS showed a similar pattern to
fresh GUS solution except there were 2 faded bands that
had almost disappeared at molecular weights 75 KDa and
55 KDa (Figure 3) with 75 KDa as one monomer in GUS
tetramer structure. The lyophilized samples had lower
intensity compared with fresh GUS. Flores et al indicated
that the quaternary structure disruption is a characteristic of
the loss of enzyme activity of GUS.29 The freeze-drying
procedure might interfere with chemical stability of mono-
mer 75 KDa and further interfere with the interactions
between the monomers.30 Therefore, degradation and par-
ticularly quaternary structural changes were 2 of the pos-
sible reasons for the enzyme activity loss.
Emitted Dose Evaluation at Different Mass Ratio of
Liposome to Carrier
To determine the amount of ingredient emitted from the
mouthpiece of the dry powder inhaler, a sampling appara-
tus was used to collect the emitted dose.31,32 Jet-milled lipo-
some powders were mixed with D-mannitol at the mass ratio
of 1:0, 1:4, 1:9, and 1:19. The mannitol was 45- to 75-μm
sieved size, which is within the range of sizes shown by Bell
et al to be suitable as a carrier.33,34 Forty milligrams of pow-
ders were put into gelatin capsule No. 3, and powders were
actuated at 60 L/min for 10 seconds. The inhaler was unable
to disperse more than 75% of the dose for any of the powder
blends used. There was a trend to a greater proportion lipo-
somes being dispersed as the ratio of mannitol was increased
(Figure 4). Percentages of the doses, 53.2%, 58.1%, 66.5%,
and 73.6% were delivered by the inhaler at the liposome
powder contents of 100%, 20%, 10%, and 5%, respectively.
Aerodynamic Fine Particle Fraction Evaluation
The 1:4 ratio of liposome to mannitol powder was used for
the aerodynamic fine particle fraction estimation due to its
relatively good dispersion potential and greater protein and
lipid amount for assay. Six capsules were emptied se-
quentially from dry powder inhaler to the twin-stage liquid
impinger. The lipid assay showed 15.6% of the lipid con-
tents were recovered from the lower stage with aerody-
namic particle sizes of less than 6.4 μm. In the upper stage
and mouthpiece-throat, 42.7% and 26.9% of the lipids
deposited with sizes larger than 6.4 μm (see Figure 5). The
total emitted dose was 85% for the 6 capsules, much higher
than the single capsule emission of 58.1%. This may be
explained by priming the DPI, mouthpiece, and throat. The
following doses benefit from this priming. The fine particle
fractions from lipid assay were slightly different from that
of protein activity assay. Active protein on the upper stage
and mouthpiece-throat were 34.0% and 21.3%, respec-
tively, less than the lipid contents percentage, but in the
lower stage there was a larger quantity of active protein
than the lipids. The total amount of lipids and total amount
of active proteins were 85.2% and 78.6%, respectively. The
unencapsulated proteins played a role in this particle size
fraction difference since they have smaller molecular sizes
Figure 1. The total amount and retained activity of GUS after
liposome preparation, lyophilization, and jet-milling (n = 2, error
bars depict range).
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than liposomal vesicle diameters, and after being dispersed,
they would most likely be deposited on the lower stage of
twin-stage liquid impinger.
The carrier mannitol particles have contact points with lipo-
some particles. The greater the quantity of carrier mannitol,
the more potential contact points exist between carrier and
liposome particles. This potential for distribution on carrier
surfaces facilitated liposome delivery. The liposomes that
impacted on the upper stage did not completely separate
from the mannitol carrier prior to impaction. Therefore,
greater energy input would be required for complete sepa-
ration of the small and large particles.
Lyophilization Optimization
Lyophilization causes loss of GUS activity. Approximate-
ly 67% (29%/43%) of the retained encapsulated proteins
had activity after lyophilization and 61% (22%/36%) after
Figure 2. SEM of liposome powders after lyophilization and jet-milling: (A) DMPC-CH-mannitol after lyophilization (original
magnification ×500); (B) DMPC-CH-mannitol after jet-milling (original magnification ×500); (C) DMPC-CH-GUS-mannitol after
lyophilization (original magnification ×500); and (D) DMPC-CH-GUS-mannitol after jet-milling (original magnification ×2500). The
scale bars are 10 μm.
Figure 3. SDS-PAGE image. Lanes 1 and 4, Fresh GUS;
lane 2, lyophilized liposomewith GUS after lipid extraction; lane 3,
micronized liposome with GUS after lipid extraction; lane 5, ly-
ophilized liposome with GUS without lipid extraction; lane 6,
micronized liposome with GUS without lipid extraction; lane 7,
mark 12 marker. Molecular weights (KDa) are indicated at the right
side of the gel. Arrows on the left indicate the bands that have
almost disappeared.
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jet-milling. In preparing the liposomes, freeze-thawing did
not change GUS activity, which indicated that during
lyophilization GUS activity was lost in the drying pro-
cess. Several studies were conducted attempting to im-
prove GUS stability in order to optimize the lyophilization
procedure.
In the absence of cholesterol, encapsulation efficiency of
DMPC liposomes was 38.7%, but after lyophilization, only
9.6% GUS retained activity compared with freshly prepared
liposomes. The presence of cholesterol may increase the
resistance of liposomal bilayers to freeze-drying stress mak-
ing it a stabilizing compound. This result is consistent with
the data of van Winden et al.35
For freeze-drying optimization, sucrose was used instead of
mannitol. The molar ratio of sucrose to lipid was 10:1. Su-
crose was selected as an alternative excipient for its capa-
city to act as a cryoprotectant and dehydroprotectant. As
a disaccharide, sucrose has glass formation with high Tg
(77°C) in amorphous state after lyophilization.36 Sucrose
can interact with membrane phospholipid head groups via
hydrogen-bonding to replace the water-lipid interaction to
stabilize the dry membrane. Mannitol is a monosaccharide
alcohol that easily crystallizes and has the tendency of phase
separation in the lyophilized cake, which is deleterious to the
stability of dry liposomes. Crystallization of saccharides
may be inhibited in the presence of povidone due to its
ability to increase the Tg of the saccharides, and the larger
molecular weight PVP, the stronger prevention of crystal-
lization.37,38 Therefore, povidone (Mw 40 K) was added to
mannitol to optimize the lyophilization process. The povi-
done assay, used 2.5% (wt/vol) povidone in mannitol solu-
tion followed by liposome preparation and lyophilization.
All other parameters were kept the same as those in the
preparation of mannitol with lipid.
After freeze-drying, 41.4%, 67.3%, and 55.8% of encapsu-
lated GUS retained activity in the presence of mannitol,
PVP-mannitol, and sucrose, respectively. After 50 days
of storage in desiccator, the retained activities were 16.9,
39.4, and 27.4, respectively (Table 1). These results in-
dicate that the presence of PVP in mannitol gave the best
retained activity for lyophilization and storage stability
after 50 days. Sucrose improved the GUS stability com-
pared with mannitol. Therefore, crystallization is most like-
ly one of the important reasons for GUS activity loss in
lyophilization.
Since sodium phosphate buffer may induce a large pH shift
in lyophilization, the same pH 7.4 HEPES buffer system
was evaluated. 58.5% activity was retained after freeze-
drying and there was no significant difference in the GUS
stability between HEPES and sodium phosphate buffer.
The existence of saccharides alone may effectively reduce
the pH shift of sodium phosphate buffer at a quite low
concentration of 20 mM.
CONCLUSION
The feasibility of lyophilization and milling for preparation
of protein, liposome dry powders for pulmonary delivery
was evaluated. β-glucuronidase was encapsulated in lip-
osomes, lyophilized, micronized, and characterized in terms
of emitted dose and aerodynamic fine particle fraction.
Figure 4. Emitted dose of GUS from a dry powder inhaler
sampled at 60 L/min for 10 seconds (n = 3, mean ± SD).
Figure 5. Aerodynamic fine particle fractions in twin-stage
liquid impinger (n = 2, error bars depict range).
Table 1. GUS Retained Activity Immediately After
Lyophilization and Upon Storage for 50 Days*
Retained Activity (%)
0 days 50 days
DMPC in mannitol 9.6 (0.6) 5.7 (0.3)
DMPC:CH (7:3) in mannitol 41.4 (5.84)† 16.9 (1.2)
DMPC:CH (7:3) in PVP
(2.5% wt/vol)-mannitol
67.3 (5.6)† 39.4 (3.5)
DMPC:CH (7:3) in sucrose 55.8 (0.3)† 27.4 (0.9)
*DMPC indicates dimyristoyl phosphatidylcholine; CH, cholesterol;
and PVP, polyvinylpyrrolidone. n = 2, mean (error depicts range).
†n = 3, mean (SD).
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Further optimization of the manufacturing processes is
required in the context of specific therapeutic proteins to
maximize stability and aerosol delivery efficiency.
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